There are good reasons to invest in Lilly and to hold off.

Hospitals now required to submit insurance claims data to qualify for discounts.

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many ...

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, ...

But at this stage of Eli Lilly's crucial obesity-drug business, the greenest pastures are currently overseas.

Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing ...

CNBC's Angelica Peebles reports on Eli Lilly's stock performance. Got a confidential news tip? We want to hear from you. Sign ...

The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.

Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?

LCCC is launching a hands-on training pipeline that places technicians directly into the pharmaceutical industry.

By Maggie Fick BRUSSELS, June 23 (Reuters) - Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker targeting the ...

By Maggie Fick and Andrew Silver BRUSSELS, June 24 (Reuters) - Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, an executive at the U.S.